Finance

Lists
Why is ANIK up 4,55%?
Dive Deeper
ANIK:NASDAQ
Anika Therapeutics Inc
USD 20,47
+4,55%
(+0,89) 1D
USD 20,47
0,00% (0,00)
After hours
Closed: 12 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANIK...
Open
USD 19,53
High
USD 20,69
Low
USD 19,32
Mkt. cap
273,95 m
Avg. vol.
89,06 k
Volume
152,58 k
52-wk high
USD 22,88
52-wk low
USD 8,67
EPS
-USD 0,27
Beta
0,21
Shares outstanding
13,38 m
No. of employees
235
Open
USD 19,53
High
USD 20,69
Low
USD 19,32
Mkt. cap
273,95 m
Avg. vol.
89,06 k
Volume
152,58 k
52-wk high
USD 22,88
52-wk low
USD 8,67
EPS
-USD 0,27
Beta
0,21
Shares outstanding
13,38 m
No. of employees
235
News stories
From web sources and news partners
About Anika Therapeutics Inc
CEO-
Employees235
Founded1983
HeadquartersBedford, Massachusetts, Verenigde State van Amerika
Sector-
Websiteanika.com
Analyst ratings
Based on 2 analysts giving stock ratings to ANIK in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ANIK in the last 3 months.
Highest
Current USD 20,47
USD 23,00 (+12,36%)
Average
USD 23,00 (+12,36%)
Lowest
USD 23,00 (+12,36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Petusky
Barrington
Buy
Maintained
USD 23,00
+12,4%
10/01/2026
Madison Elsaadi
B. Riley Securities
Buy
Initiated
USD 23,00
+12,4%
09/18/2026
Anderson Schock
B. Riley Securities
Buy
Maintained
USD 21,00
+2,6%
07/30/2026
Last report
29 Jul. 2026
Fiscal period
Q2 2026
USD 0,42 / USD 0,03
+1 300,00%beat
Revenue / Est. (USD)
32,61 m / 29,21 m
+11,62%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
27,82 m
30,62 m
29,61 m
32,61 m
Cost of goods sold
12,23 m
11,44 m
10,62 m
11,37 m
Cost of revenue
12,23 m
11,44 m
10,62 m
11,37 m
Research and development expenses
6,95 m
6,45 m
6,71 m
7,34 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,87 m
12,08 m
16,18 m
10,18 m
Operating expense
18,82 m
18,53 m
22,90 m
17,52 m
Total operating expenses
31,05 m
29,97 m
33,51 m
28,88 m
Operating income
-3,23 m
646,00 k
-3,90 m
3,73 m
Other non operating income
-
-
-
-
EBT including unusual items
-2,24 m
764,00 k
-4,82 m
3,38 m
EBT excluding unusual items
-2,24 m
764,00 k
-3,23 m
4,15 m
Income tax expense
939,00 k
-1,04 m
235,00 k
71,00 k
Effective tax rate
-41,99%
-135,73%
-4,87%
2,10%
Other operating expenses
-
-
-
-
Net income
-2,33 m
292,00 k
-5,06 m
3,31 m
Net profit margin
-8,37%
0,95%
-17,07%
10,15%
Earnings per share
0,04
0,31
0,27
0,42
Interest and investment income
997,00 k
118,00 k
667,00 k
426,00 k
Interest expense
-
-
-
-
Net interest expenses
997,00 k
118,00 k
667,00 k
426,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,83 m
1,96 m
-2,49 m
5,23 m
Gain or loss from assets sale
-451,00 k
790,00 k
-52,00 k
-32,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme